Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial

BACKGROUND: The treatment of acute promyelocytic leukemia (APL) has been revolutionized in the past two decades by the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). It suggests that non-high-risk APL patients can be cured without chemotherapy. However, ATRA plus chemotherapy i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Trials
Päätekijät: Zhang, Xinxin, Zhang, Huiyun, Chen, Limei, Wang, Mengchang, Xi, Jieying, Liu, Xin, Xie, Ming, Li, Dengzhe, Gulati, Ekamjyot Singh, Gong, Sha, Wang, Huaiyu
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Study Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6126003/
https://ncbi.nlm.nih.gov/pubmed/30185214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-018-2812-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia